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a schedule with IMiDs pre-treatment may improve the depth and du-
ration of response of MM patients both as upfront therapy and in the
relapsed/refractory setting.
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Flow Cytometry (FC) is a powerful technique in both diagnosis and
Minimal Residual Disease (MRD) identification in multiple myeloma
(MM) patients. However, most of data were obtained into controlled
clinical trials and if MRD assessment by FC is routinely applicable to
clinical practice is so far under consideration. From January 2011 to Jan-
uary 2015, 37 consecutive MM patients, median age 73 years (57-83)
treated with a program containing Bortezomib, Melphalan and Pred-
nisone (VMP) for a total of 9 courses entered the study. Plasma-cells
(PC) FC characterization was performed on bone marrow (BM) samples
using a 6-colors panel of antibodies (Fitc/PE/PerCP/PE-Cy7/APC/APC-
Cy7) evaluating the cy-Ig lambda/cy-Ig kappa light chains expression
on CD19 CD38 CD56/CD117 CD45 surface markers, for a total of 19
kappa/lambda ratio evaluations. BM B lymphocytes were used as in-
ternal control for cy-Ig light chains expression. The analysis was per-
formed at diagnosis and after 30-60 days from the end of the last course
of treatment for flow-MRD assessment. Patients were considered flow-
MRD negative when pathological PC were undetected in the BM sam-
ples at the FC sensitivity limit of 10-5 cells. A mean of 15420 PC was
analyzed for MRD assessment, allowing a maximum sensitivity of de-
tection of 0.0001% in all cases. At the end of VMP, 18 patients (48%)
achieved a standard CR, 10 a VGPR, 3 a PR and the remaining 6 a
SD/PD (three of these did not complete the treatment for progression
of disease). Among 18 patients in CR, 12 (67%) were flow MRD-neg-
ative and 6 (33%) flow MRD-positive. Overall, MRD negativity by FC
assessment is the better marker of clinical outcome in terms of PFS (2y-
PFS: 90% vs 52% for flow MRD negative and positive, respectively;
P=0.003). Moreover, among patients in standard CR, 2y-PFS of flow-
MRD negative patients was significantly better than MRD positive
(P=0.012). As previously documented on MM patient after autologous
hematopoietic stem cell transplant, FC remission through cy-Ig light
ratio on PC subpopulations is a low-cost, sensitive and applicable MRD
assay, a powerful tool in treatment response evaluation and a crucial
marker of outcome in MM.
P194
A NOVEL IN-HOUSE DEEP-SEQUENCING METHOD FOR NON-INVASIVE DISEASE
MONITORING IN MULTIPLE MYELOMA PATIENTS
C. Carniti, G. Biancon, S. Gimondi, A. Vendramin, A. Bermema,
S. Rizzitano, M. Magni, N. Bolli, V. Montefusco, P. Corradini
Fondazione IRCCS Istituto Nazionale Tumori, Università degli Studi di Milano
Background: Novel and more effective treatment strategies have sig-
nificantly prolonged multiple myeloma (MM) survival and raised inter-
est in the depth of response. This implies the need of highly sensitive
assays such as the determination of minimal residual disease (MRD) by
multiparametric flow cytometry (MFC) and next generation sequencing
(NGS) of immunoglobulin (IGH) gene rearrangements. Ongoing studies
are examining circulating cell-free tumor DNA (cfDNA) as a sensitive
measure of small amounts of residual cells. In the present study, we de-
scribe and analytically validate a simplified in-house deep-sequencing
method to identify and quantify residual tumor burden in MM patients
from plasma samples. Methods: We retrospectively analyzed 25 MM
paired tumor (n=25) and plasma samples (n=48) obtained at diagnosis
and at specified time points during treatment. Genomic DNA (gDNA)
and cfDNA were extracted from selected CD138+ plasma cells (PC) and
from plasma (Qiagen). IGH gene rearrangements were amplified, qual-
ity assessed (Agilent hsDNA kit) and sequenced on Ion Torrent PGM.
Raw reads were filtered and aligned using IMGT germline database and
aggregated into clonotypes. Post-processing analyses were performed
using VDJtools and customized R scripts. Results: Our sequencing
method successfully identified a IGH MM clonotype in 88% of tumor
samples (22/25), subsequently detected in plasma of all 22 cases (me-
dian 4.7% of total filtered reads). Levels of the IGH clonotype in cfDNA
distinguished between groups of patients with different prognosis: pa-
tients with levels >4.7% prior to therapy, had significantly shorter PFS
than patients with levels<4.7% (median 268 vs 990 days; HR=3.532,
P=0.04827, Log-rank). IGH cfDNA levels over the median were signif-
icantly associated with higher risk of disease progression (HR=7.9,
P=0.0384). cfDNA levels reflected the number of PC enumerated by
MFC (r=0.7249, P<0.0001, Pearson’s correlation test). Accordingly, TTP
was significantly longer (P<0.0001) for patients displaying frequencies
lower than 10-5 (TTP 9±3 months, mean±SD, for frequencies>10-5 vs
15±5 months for frequencies=10-5 vs 37±4 months for frequencies<10-
5). Those patients are in CR and characterized by PC frequencies <10-
5 by MFC, and are therefore defined as MRD-negative. Conclusions:
Results of this study support the clinical applicability of quantifying
tumor levels by our in-house deep-sequencing of IGH gene rearrange-
ments in plasma of MM patients.
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Aim: To outline a picture of the world of patients (pts) with myeloma
and their caregivers (cgs) trying to identify their unmet needs and to
explore how they face this distressing experience inside and outside
the hospital. Methods: Pts and cgs filled in some questionnaires regard-
ing their satisfaction, at the time of enrolment and after 6 months (t0
and t1). Pts were also evaluated for their fitness with: non-instrumental
and Instrumental Activities of Daily Living (ADL and IADL), Study of
Osteoporotic Fractures (SOF), Geriatric Depression Scale (GDS) and
Cumulative Illness Rating Scale (CIRS). Cgs were evaluated with Care-
giver Burden Scale (CBS). One hundred seventy two pts were included
in the study,136 of which (79.1%) had a cgs. Results: Features of pts and
cgs at t0 are reported in Table1. A quarter of pts were at disease onset
(≤1year), 28% were on treatment. Basing on the questionnaires,in case
of emergency about half of pts ask for help firstly to cgs, while most of
cgs ask general practitioner. Median (mdn) satisfaction level for global
hospital service was high in both groups. Mdn cgs burden scale was 10.
Forty-six pts (27%) were defined depressed (GDS≥2). Most of pts
reached showed a high score for ADL and IADL and IADL was higher
in males vs females (85% vs 70%,p=0.025). Eighty-nine pts (52%) were
defined frail (at least one SOF criteria) and these were older than the
others (67 vs 63 years,p=0.020). Mdn score for psychiatric pathologies,
severity and comorbidity were 2, 0.07 and 0. No difference in ADL,
IADL, SOF scales and in severity and comorbidity indexes were found
according to the duration and the phase of disease at t0 (all p>0.1). After
6 months,135 pts (78.5%) were evaluated again. Percentage of frail pts
decreased among pts with a duration of disease >1year (t0:48%
t1:33%,p=0.009) and among pts treatment-free at t0 (t0:47%
t1:29%,p=0.004). Mdn severity and comorbidity indexes decreased
(p<0.001) with no difference according to the duration of disease and
to the disease phase at t0 (all p>0.4). Mdn score for psychiatric patholo-
gies decreased in the whole cohort (t0:2 t1:0,p=0.012), in pts at disease
onset (t0:2 t1:0,p=0.006) and in pts treatment-free at t0 (t0:1
t1:0,p=0.043). ADL and IADL did not change (p=0.5 and p=0.8). Con-
clusions: When dealing with a complex disease as myeloma, it is impor-
tant to extent the health professional intervention to an accurate
evaluation of the emotional and practical difficulties of people (pts and
cgs) who have to face such a distressing experience.
128 | haematologica| 2017; 102(s3)
